UMHAT "Alexandrovska" EAD
Welcome,         Profile    Billing    Logout  
 0 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stefanova-Petrova, Diana
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
Kolarova, Nataliya
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
Tarnev, Ivaylo
ENSURE-1, NCT05134441 / 2021-000028-36: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Recruiting
3
1050
Europe, US, RoW
IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium
Immunic AG, Immunic AG
Multiple Sclerosis
09/24
09/32
CALLIPER, NCT05054140 / 2021-000048-23: Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Active, not recruiting
2
450
Europe, Canada, US, RoW
IMU-838, Vidofludimus calcium, Placebo matching IMU-838, Placebo Arm
Immunic AG
Multiple Sclerosis
01/25
01/25
Traykov, Latchezar
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
ENSURE-1, NCT05134441 / 2021-000028-36: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Recruiting
3
1050
Europe, US, RoW
IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium
Immunic AG, Immunic AG
Multiple Sclerosis
09/24
09/32

Download Options